Tranzyme (TZYM) Gets $9.3M in Additional Funds in New Term Loan Agreement
Tweet
Share
E-mailGet Alerts TZYM Hot Sheet
Join SI Premium – FREE
Tranzyme Pharma (Nasdaq: TZYM) today announced that it received an additional net $9.3 million in term loan proceeds through an amendment and restatement of its existing debt financing facility with Oxford Finance LLC and Horizon Technology Finance Corporation (Nasdaq: HRZN).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
- CoVolt Power files for proposed IPO
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
